Ohio-based, medical-device-focused clinical research organization NAMSA acquired German full-service CRO Clinical Research Institute for an undisclosed price, expanding its operations into the European market.
Founded in 2011, CRI offers medtech developers in Europe end-to-end services.
NAMSA, which was acquired by healthcare private equity firm ARCHIMED in 2020, didn’t disclose the purchase price for CRI. Under ARCHIMED, NAMSA has made eight acquisitions to expand its global and service operations, the company said in a July 18 press release.
“The addition of this organization to the NAMSA family is a significant move for us in Germany that enhances and expands our CRO offerings throughout Europe and across all markets,” NAMSA CEO Christophe Berthoux said in the release.
NAMSA’s clinical research services provide clinical study management, postmarket studies, biostatistics and data management, safety reporting and imaging core lab services.
The company went on a CRO buying spree shortly after being bought by the private equity group, racking up three acquisitions in a 12-month period and adding Berthoux as its CEO. By the end of that run, NAMSA had reeled in Philadelphia-based Clinlogix, New York-based Syntactx and Minneapolis-based American Preclinical Services.